Sponsor
Maxine Dexter
Representative · D-OR
The bill strengthens FDA and customs authority to keep unsafe imported drugs out of U.S. markets—improving public health protection and enforcement clarity—but does so at the cost of higher compliance burdens, potential delays or reduced access to some imported therapies, and increased scope for administrative discretion.
Patients and the public: FDA can more quickly exclude or control unsafe imported drugs (not limited to controlled substances), reducing exposure to harmful or misbranded products at the border.
Customs/Treasury and enforcement agencies: Aligning import-admissibility language lets customs authorities act more consistently on orders covering drugs generally, improving enforcement against inadmissible or dangerous imports.
FDA/HHS leadership and healthcare providers: Explicitly clarifies chain of authority for biologics by naming the CBER Director (or senior officials), reducing administrative ambiguity and speeding decision-making on biologics regulation.
Patients relying on niche or imported therapies: Broader detention authority could delay or reduce access to certain imported drugs or biologics, potentially interrupting care for vulnerable patients.
Importers, small suppliers, and some health providers: Expanding regulatory reach increases compliance burdens, shipment delays, and costs associated with detentions or exclusions at the border.
Healthcare providers and regulated parties: Broader and vaguer statutory language raises the risk of regulatory overreach and administrative discretion, creating due-process and rights concerns for lawful but controversial products.
Based on analysis of 2 sections of legislative text.
Expands certain FDA statutory references from “controlled substances” to all “drugs” and explicitly includes the CBER Director in a key cross‑reference.
Representative · D-OR
Amends FDA statutes to change several legal references from “controlled substances” to the broader term “drug,” and clarifies that the Director of the Center for Biologics Evaluation and Research (or senior officials) is included in an official cross‑reference. The changes make an existing import/ admissibility and public health authority apply to all drugs rather than only to controlled substances, aligning cross‑references in import law with that broader scope. The effect is a technical but meaningful expansion of the statutory language that can allow FDA and related officials to rely on an existing inadmissibility/authority provision for a wider set of products, and clarifies which FDA leadership is covered by the cross‑reference for enforcement and decisionmaking.
Official title: To amend the Federal Food, Drug, and Cosmetic Act to expand certain authorities with respect to the recall of controlled substances to apply with respect to all drugs, and for other purposes.
Introduced March 18, 2026 by Maxine Dexter · Last progress March 18, 2026